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INTRODUCTION
In the last updated Guideline, “Management of Hypertensive 
Disorders of Pregnancy”, in 2014, the Society of Obstetric Medicine 
of Australia and New Zealand recommends assessment of mater-
nal medical and obstetric history for risk indicators that predis-
pose women to pre-eclampsia (PE). Women who are considered at 
high risk are recommended prophylactic treatment with low-dose 
aspirin,1 as randomised trials and meta-analyses have shown a 
reduction in the risk of disease with this intervention.2,3
Unfortunately, the prediction of PE with maternal history 
alone is limited. When history-based screening is used, just 40% 
of women who will develop preterm PE are identified.4 As a result, 
up to 60% of women who would otherwise benefit from aspirin 
do not receive the necessary prophylaxis.5,6 Furthermore, within 
the high-risk population group, rates of aspirin prophylaxis are 
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The current approach to screening for pre-eclampsia is based on guidelines that 
rely on medical and obstetric history in early pregnancy to select a high-risk group 
that might benefit from low-dose aspirin. However, combined screening tests 
with the addition of biophysical and biochemical measurements have shown sig-
nificantly better detection rates for preterm pre-eclampsia. Furthermore, the ad-
ministration of aspirin for the 10% screen-positive group can lead to a significant 
reduction in severe and preterm forms of pre-eclampsia. This review aims to an-
swer frequently asked questions related to the clinical implementation of screen-
ing and the management of screening results.
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just 12–24%.6,7 An alternative approach is to use predictive tests 
based on competing risks or logistic regression models to esti-
mate the individual probability of developing PE using maternal 
demographic characteristics, medical and obstetric history, and 
biomarkers.8-11 The Fetal Medicine Foundation (FMF) algorithm 
has a significantly higher detection rate for preterm PE, and it 
might therefore improve outcomes when implemented.5,12
This article aimed to answer common questions in routine 
clinical practice about the combined screening test for PE.
WHAT IS A GOOD SCREENING TEST?
A good screening test should identify important health problems 
at asymptomatic or early stages of disease, be easily accessible, 
fast, economically balanced and should have a reasonably accept-
able false positive rate to minimise possible harm from unnec-
essary intervention.13 An accurate screening test for PE is highly 
desirable, because PE is a significant cause of maternal and peri-
natal morbidity and mortality, and an effective, safe and cost-ef-
fective preventative strategy is available.14
WHAT IS THE PROPOSED METHOD OF 
SCREENING FOR PE ACCORDING TO 
WIDELY USED CURRENT GUIDELINES?
The Society of Obstetric Medicine of Australia and New Zealand 
advises screening for all women at their first prenatal visit by as-
sessing for predisposing risk indicators according to maternal 
demographic characteristics, and medical and obstetric history.1 
These guidelines are endorsed by the Royal Australian and New 
Zealand College of Obstetricians and Gynaecologists. In their own 
prenatal screening statement from 2015,15 the Royal Australian 
and New Zealand College of Obstetricians and Gynaecologists 
also acknowledged the potential role for ultrasound and bio-
chemical markers in the prediction of PE. The authors recognised 
the need for further research to support the use of biomarkers for 
first trimester PE screening, and as such have not yet endorsed 
a combined screening approach. However, this guideline is cur-
rently for review, and the recommendations might change in light 
of the large amount of evidence published in the past 3 years.
In 2013, the American College of Obstetricians and 
Gynaecologists (ACOG) recommended screening by taking an 
accurate history,16 and declared a pregnancy as high risk in the 
presence of at least one risk indicator. Interestingly, the 2013 
guidelines proposed the use of aspirin only in patients with a 
history of either early-onset PE with delivery before 34 weeks of 
gestational age, or for women with more than one previous preg-
nancy complicated by PE. In the following year, the US Preventive 
Services Task Force reported a more generous indication for aspi-
rin and recommended its use not only in women considered to be 
at ‘high risk’, but also those with ‘several’ moderate risk indicators 
in their history.16 These recommendations have since been en-
dorsed in the recently updated ACOG guidelines.17
Similar to the new approach by ACOG, the National Institute 
for Health and Care Excellence (NICE) in the UK identifies high-risk 
pregnancies by the distinction between major- and moderate-risk 
indicators according to maternal characteristics and medical his-
tory.18 The scoring systems proposed by different Obstetrics and 
Gynaecology societies, and their predictive performances are 
summarised in Tables 1 and 2, respectively.
WHAT IS THE PERFORMANCE OF 
SCREENING BASED ON MATERNAL 
HISTORY ACCORDING TO CURRENT 
WIDELY USED GUIDELINES?
Although recommended by many Obstetrics and Gynaecology soci-
eties, screening tests based on maternal characteristics and history 
alone perform poorly.5 Detection rates (DR) using the NICE guidelines 
are 39% (95% CI 27–53%) and 34% (95% CI 27–41%) for preterm PE 
(delivery <37 weeks), and term PE (delivery > 37 weeks) respectively, 
at a 10.2% screen-positive rate (SPR). The screening approach advised 
by ACOG in 2013, where only one positive risk indicator is required 
to be identified as high risk, shows a DR of 90% (95% CI 79–96%) 
for preterm PE and 89% for term PE, with a high SPR of 64.2%.5 
According to the 2013 ACOG criteria for the use of aspirin based on 
obstetric history alone, the DR is 5% for PE <37 weeks and 2% for 
PE ≥37 weeks, at a 0.2% SPR.5 Individual-risk calculation using the FMF 
algorithm with maternal history alone identifies 41% (95% CI 28–54%) 
of preterm PE and 37% (95% CI 30–45%) of term PE at a 10% SPR.5
WHAT IS THE SCREENING PERFORMANCE OF 
INDIVIDUAL RISK CALCULATION 
FOR PRETERM PE AND TERM PE 
WITH THE ADDITION OF BIOPHYSICAL AND 
BIOCHEMICAL MARKERS?
Several models have been developed for the prediction of 
PE.8-10,19-21 Most of these models are derived from logistic regres-
sion analysis with relatively small sample sizes, and lack internal 
and external validation.9,10 The earlier version of the FMF algo-
rithm was also based on logistic regression analysis,21 and was re-
cently updated with a larger dataset of >35 000 pregnancies using 
a competing risks model.8 The FMF algorithm has been validated 
in different settings, including in the Australian population.5,22-24
The new FMF competing risks model assumes that all women 
would develop PE if they remained pregnant indefinitely. The al-
gorithm estimates the distribution of disease across gestation by 
combining maternal characteristics and history with the results 
of biophysical (mean arterial pressure (MAP), mean uterine artery 
pulsatility index), and biochemical measurements (serum pregnan-
cy-associated plasma protein-A and/or serum placental growth 
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factor (PLGF)).8 The patient-specific probability of requiring delivery 
with PE at or below a defined gestational age can then be calcu-
lated.8 This algorithm is embedded in a few commercially available 
ultrasound reporting systems, and there is a free access risk cal-
culator at https ://fetal medic ine.org/resea rch/asses s/preec lampsia.
Studies have shown that the highest detection rate for PE 
is achieved using the FMF algorithm with a combination of ma-
ternal characteristics and history, MAP, mean uterine artery 
pulsatility index, and PLGF. In the ASpirin for evidence-based 
PREeclampsia prevention (ASPRE) trial, a risk cut-off of 1:100 led 
to a DR of 76.7% for preterm PE, but just 43.1% for term PE, at 
9.2% false positive rate (FPR).25 The test performs best for the 
detection of early-onset disease with detection rates ranging be-
tween 90 and 100% for PE <34 weeks and PE <32 weeks, respec-
tively.8,22,23 Although less common, early-onset disease has the 
greatest impact on maternal and fetal morbidity and mortality, 
and as such its prediction is important to improving health out-
comes in PE.26
The FMF model has been internally and externally vali-
dated,4,6,22,23 and is now acknowledged by the International Society 
of Ultrasound in Obstetrics and Gynecology as the most effective, 
and where resources are available, the preferred screening strategy 
for PE.12 In the recent World Congress of Gynecology and Obstetrics, 
the International Federation of Gynecology and Obstetrics sug-
gested that all women should be offered first trimester combined 
screening for preterm PE, and in rural or limited resource settings, 
variations of the screening method should be considered.
The risk cut-off used in PE screening is determined by: (i) the 
background prevalence of PE in a given population; (ii) the accepted 
SPR for treatment with aspirin; and (iii) cost-effectiveness analysis.27 
TABLE 1 Risk indicators and indication for aspirin according to the Society of Obstetric Medicine of Australia and New Zealand, 
National Institute for Health and Care Excellence, US Preventive Services Task Force and American College of Obstetricians 
and Gynaecologists
SOMANZ-RANZOG NICE 2010 USPSTF 2014 ACOG 2018
Risk factors High-risk factors High-risk factors High-risk factors
Previous pregnancy with PE Previous pregnancy with PE Previous pregnancy with PE Previous pregnancy with PE
Chronic hypertension Chronic hypertension Chronic hypertension Chronic hypertension
Autoimmune disease Autoimmune disease Systemic lupus erythematosus Systemic lupus erythematosus
Diabetes mellitus Diabetes mellitus Diabetes mellitus Diabetes mellitus
Chronic kidney disease Chronic kidney disease Chronic kidney disease Chronic kidney disease
Multifetal gestation   Multifetal gestation Multifetal gestation
Nulliparity   Thrombophilia Thrombophilia




BMI at first visit >35 kg/m2 Age >40 years Age >35 years Age >35 years
Family history of PE Interpregnancy 
interval >10 years
Interpregnancy interval >10 years Inter-pregnancy interval >10 years
Conception by IVF BMI at first visit >35 kg/m2 BMI >30 kg/m2 BMI >30 kg/m2
  Family history of PE Family history of PE Family history of PE
    History of SGA or adverse outcome History of SGA or adverse outcome
    Sociodemographic characteristics 
(African American race or low 
socioeconomic status)
Sociodemographic characteristics 
(African American race or low 
socioeconomic status)
Indication for aspirin: Indication for aspirin: Indication for aspirin: Indication for aspirin:
Moderate- to high-risk for 
PE (no clear distinction of 
moderate and high risk)
2 moderate or 1 high-risk 
factor
1 high-risk factor 1 high-risk factor
Dose: unclear Dose: 75 mg/day from 
12 weeks
Dose: 81 mg/day optimally before 
16 weeks
Dose: 81 mg/day optimally before 
16 weeks
Until 37 weeks or until 
delivery
Continue daily until delivery Continue daily until delivery Continue daily until delivery
    Consider aspirin: Consider aspirin:
    If more than one moderate risk factors Other established medical indications
ACOG, American College of Obstetricians and Gynaecologists; BMI, body mass index; IVF, in vitro fertilisation; NICE, National Institute for Health 
and Care Excellence; PE, pre-eclampsia; SGA, small-for-gestational age; RANZCOG, Royal Australian and New Zealand College of Obstetricians and 
Gynaecologists; SOMANZ, Society of Obstetric Medicine of Australia and New Zealand; USPSTF, US Preventive Services Task Force.
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As with screening for chromosomal abnormalities, an audit pro-
gram should be carried out, and equations for risk calculation, mul-
tiples of the median of the biomarkers and risk cut-offs might need 
to be adapted to local populations in different settings.27-29
CAN SCREENING FOR PE BE PERFORMED 
IN MULTIPLE PREGNANCIES?
As the background risk for PE in twins is higher than in singletons, 
the combined screening for PE has a poorer performance in mul-
tiple pregnancies, resulting in a very high SPR to achieve reason-
able sensitivity.30,31 Most national guidelines recommend aspirin 
for twin pregnancies with one additional risk indicator, and as a 
result, the majority of this subgroup already receives prophylaxis. 
However, efficacy studies for aspirin in multiple pregnancies are 
lacking. Given insufficient evidence, and the high SPR, the use of 
this screening test in multiple pregnancies is debatable.
HOW SHOULD WE MANAGE LOW-RISK 
RESULTS AT FIRST TRIMESTER SCREENING 
FOR PE IN PATIENTS WITH A POSITIVE 
HIGH-RISK HISTORY? IS IT NECESSARY TO 
PERFORM FIRST TRIMESTER SCREENING 
FOR PE IN HIGH-RISK PATIENTS?
A subgroup analysis of the ASPRE trial showed that patients who 
are identified as screen-positive according to the NICE or ACOG 
guidelines, but are screen-negative with combined screening, 
have a lower risk of preterm PE than the background risk in the 
obstetric population (NICE: 0.65% (95% CI 0.25–1.67%) ACOG: 
0.25% (95% CI 0.18–0.33%)).32 This is reassuring for patients as well 
as care providers. In contrast, considering the limitations of PE 
screening, which might fail to detect up to 24% of preterm PE, the 
advice regarding aspirin therapy and follow up for this subgroup 
should be individualised. Furthermore, a subgroup analysis of the 
ASPRE study showed that the incidence of preterm PE might not 
be influenced by aspirin in patients with chronic hypertension.33 
However, the ASPRE trial was underpowered for subgroup analy-
ses, and these results should be interpreted with caution. Given 
aspirin is safe and further confirmation is still lacking, patients 
with chronic hypertension should still be offered aspirin therapy.
HOW CAN COMBINED SCREENING FOR PE 
BE USED IN WOMEN UNDERGOING CELL-
FREE DNA TESTING INSTEAD OF FIRST 
TRIMESTER COMBINED SCREENING FOR 
FETAL ANEUPLOIDIES?
Offering cell-free DNA testing as a primary screening tool for tri-
somy 21 has shown convincing results.34 In women opting for this 
aneuploidy screening modality, first trimester ultrasound is still 
recommended to confirm normal fetal development,35 and PLGF 
can be measured alongside cell-free DNA for the calculation of PE 
risk. Some services are now offering screening for PE including 
PLGF with cell-free DNA testing as a package.
TABLE 2 Detection rates by using different screening methods
Method of screening
PE <32 weeks PE <37 weeks PE ≥37 weeks
FPR (%)DR % (95% CI) DR % (95% CI) DR % (95% CI)
NICE 41 (18–67) 39 (27–53) 34 (27–41) 10.2
ACOG 2013 94 (71–100) 90 (79–96) 89 (84–94) 64.2
ACOG 2013 for aspirin use 6 (1–27) 5 (2–14) 2 (0.3–5) 0.2
ACOG 2018 Not evaluated
USPSTF 2014 Not evaluated
SOMANZ 18.6* Not evaluated
FMF: maternal factors 53 (28–77) 41 (28–54) 37 (30–45) 10
FMF: maternal factors plus
 MAP 71 (44–90) 47 (34–61) 37 (30–45) 10
 UtA-PI 82 (57–96) 61 (47–73) 39 (32–47) 10
 MAP, UtA-PI 94 (71–100) 71 (58–82) 41 (34–49) 10
 MAP, UtA-PI, PAPP-A 94 (71–100) 69 (56–81) 42 (35–50) 10
 MAP, UtA-PI, PLGF 100 (80–100) 69 (56–81) 43 (36–51) 10
 MAP, UtA-PI, PAPP-A, PLGF 100 (80–100) 80 (67–89) 43 (35–50) 10
ACOG, American College of Obstetricians and Gynaecologists; DR, detection rate; FMF, Fetal Medicine Foundation; FPR, false positive rate; MAP, 
mean arterial pressure; NICE, National Institute for Health and Care Excellence; PAPP-A, pregnancy-associated plasma protein-A; PE, pre-eclamp-
sia; PLGF, placental growth factor; USPSTF, US Preventive Services Task Force; UtA-PI, mean uterine artery pulsatility index.
SOMANZ guidelines performance evaluated for all PE cases with no discrimination of gestational age.7 Adapted from O'Gorman et al.,5 with permission.
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HOW CAN COMBINED 
SCREENING BE IMPLEMENTED IN 
LOW-RESOURCE SETTINGS?
Various combinations of biophysical and biochemical markers 
in the FMF algorithm can be used to achieve different detection 
rates (Table  2).6,8 Where serum biochemistry is not affordable 
or accessible, the use of the uterine artery Doppler and MAP 
leads to a reasonable detection rate with minimal increase in 
cost. A study carried out in a low-resource area of Brazil using 
maternal history and MAP achieved a detection rate of 67% for 
preterm PE.36
CAN COMBINED SCREENING FOR PE 
BE PERFORMED IN THE SECOND OR 
THIRD TRIMESTER?
Second trimester screening using maternal factors, mean uterine 
artery pulsatility index, MAP and PLGF at 19–24 weeks of gestation 
is of superior predictive value to first trimester screening. Studies 
have shown that screening at 19–24 weeks is associated with a 
prediction of 99% for early PE, 85% for preterm PE and 46% for 
term PE, at FPR of 10%.37 This detection rate improves further 
when combined screening is carried out at 30–34 weeks of gesta-
tion, where it predicts 98% (95% CI 88–100%) of preterm PE and 
49% (95% CI 42–57%) of term PE, at a FPR of 5%.38 The best detec-
tion rate for term PE of 70% (10% FPR) is reached at 35–37 weeks 
of gestation by adding MAP, PLGF and sFLT-1.39
Although screening at later gestations performs better be-
cause of its proximity to the event, and may allow for increased 
surveillance and tailored models of care, late prophylactic in-
terventions have not been proven to reduce the risk of the dis-
ease. Although aspirin may still be beneficial when initiated after 
16 weeks of gestation,40 this finding has not been consistent in the 
literature, and its maximum prophylactic effect seems to occur 
when started early.41
HOW SHOULD WE FOLLOW UP PATIENTS 
WHO SCREEN POSITIVE FOR PE?
Given its excellent detection of preterm PE, a positive screening 
result should inform closer follow up for signs of PE. In the setting 
of suspected PE after 20 weeks of gestation, the implementation 
of sFLT-1/PLGF ratio with its excellent negative predictive value 
of 99.3% (95% CI 97.9–99.9%) for the development of PE within 
1 week can also help in the clinical decision-making process.42
In women who have been noted to have a higher MAP in the 
first trimester, commencement of antihypertensives should be 
considered, as less tight control of severe hypertension has been 
associated with adverse maternal and perinatal outcomes.43
Women who are screen-positive also have a higher incidence 
of small-for-gestational age infants than the general obstet-
ric population.14 Therefore, serial assessment of fetal growth 
is recommended in the third trimester. A secondary analysis of 
the ASPRE trial14 suggested a reduction in the total number of 
small-for-gestational age infants with screening and treatment of 
high-risk women with aspirin.44 Previous meta-analyses have also 
suggested a significant reduction in the risk of stillbirth, preterm 
birth and small-for-gestational age when treatment with low-dose 
aspirin is initiated.2,45
IS COMBINED SCREENING FOR PE COST-
EFFECTIVE? COSTS ASSOCIATED WITH 
SCREENING, DIAGNOSIS AND TREATMENT 
FOR PE
Cost-effectiveness depends on various factors, which are not 
always clearly ascertainable. The cost of the screening test, im-
plementation of preventative interventions and closer follow up 
need to be compared with cost savings from prevention of PE, 
preterm delivery, and long-term morbidity for mother and child. 
There is a growing body of evidence that especially early-onset 
PE and extreme prematurity are associated with an increased 
economic burden.26,46,47
The ASPRE trial showed an impressive reduction of preterm 
PE14 with a secondary analysis also showing a shorter length of 
stay (on average 20 days less) in the neonatal intensive care unit 
in the aspirin group as compared with the placebo group (68% 
reduction, 95% CI 20–86%). This was mainly achieved by reducing 
the number of preterm deliveries before 32 weeks of gestation 
with PE,48 with a cost saving of $US560 per woman screened.48 
Further studies focusing on improvement of other maternal and 
perinatal outcomes, costs related to screening and follow up 
of high-risk women, and impact on long-term morbidity are re-
quired. Recently, a decision-tree model convincingly showed that 
implementation of PE screening with administration of aspirin to 
high-risk women could save more than $14 000 000 CAD per year 
compared with the current approach in Canada.49
WHY NOT OFFER ASPIRIN TO ALL 
PREGNANT WOMEN?
Prevention of PE with aspirin seems to be safe and inexpensive. 
For these reasons, universal prophylaxis has been discussed.50 
However, aspirin prophylaxis for PE has predominantly been eval-
uated in high-risk patients, and it may not have the same effect 
in low-risk women.51 There is concern that if aspirin is prescribed 
universally without screening, it would likely reduce overall adher-
ence, and may increase the prevalence of side-effects. In addition, 
adherence could be weaker in high-risk women who are not ex-
plicitly being identified as such. In pregnancy, this is compounded 
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by the general advice that it is beneficial to avoid unnecessary 
medication. Recently, routine use of aspirin has been tested in 
low-risk women to assess acceptability with reported good ad-
herence of 90%. However, half of the women approached de-
clined randomisation, because they did not want to take aspirin 
without a good reason.52 Furthermore, rates of minor vaginal 
bleeding and postpartum haemorrhage (without influencing the 
need for blood transfusion) were higher in the aspirin group. 
Further studies are also required to assess safety and efficacy in 
low-risk populations.52
CONCLUSION
Combined screening for PE at 11–14  weeks of gestation shows 
good detection rates for early and preterm PE, and is superior to 
the current recommended approach by the Society of Obstetric 
Medicine of Australia and New Zealand, NICE and ACOG guide-
lines. This patient-specific approach is now acknowledged and 
supported by international bodies, and further trials with a focus 
on cost-effectiveness, and the affects on other maternal and peri-
natal outcomes are likely to follow in the near future.
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